Evidence map›Paper›PMID 36381325›Full record

ReviewAmerican journal of cancer research2022

Roles of Krüppel-like factor 6 splice variant 1 in the development, diagnosis, and possible treatment strategies for non-small cell lung cancer.

Kang Hu, Chao Ma, Ruijie Ma, Qiming Zheng, Yepeng Wang, Nan Zhang, Zhigang Sun

Open access · greenAbstract readReview
In one paragraph

Review in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kang HuDepartment of Thoracic Surgery, Central Hospital Affiliated to Shandong First Medical University Jinan 250013, Shandong, China.
Chao MaSchool of Clinical Medicine, Weifang Medical University Weifang 261053, Shandong, China.
Ruijie MaCheeloo College of Medicine, Shandong University Jinan 250013, Shandong, China.
Qiming ZhengCheeloo College of Medicine, Shandong University Jinan 250013, Shandong, China.
Yepeng WangDepartment of Thoracic Surgery, Central Hospital Affiliated to Shandong First Medical University Jinan 250013, Shandong, China.
Nan ZhangDepartment of Breast Disease Center, Central Hospital Affiliated to Shandong First Medical University Jinan 250013, Shandong, China.
Zhigang SunDepartment of Thoracic Surgery, Central Hospital Affiliated to Shandong First Medical University Jinan 250013, Shandong, China.
Jinan Central Hospital · CNShandong University · CNWeifang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Krüppel-like factor 6 (KLF6) is a nuclear transcriptional regulator found in mammalian tissue that has been identified as a tumor suppressor gene in several malignancies. As a result of loss of heterozygosity, DNA methylation, and alternative splicing, it is frequently inactivated in various malignancies. Krüppel-like factor 6 splice variant 1 (KLF6-SV1), Krüppel-like factor 6 splice variant 2, and Krüppel-like factor 6 splice variant 3 alternatively spliced isoforms that emerge from a single nucleotide polymorphism in the KLF6 gene. KLF6-SV1 is generally upregulated in multiple cancers, and its biological function is well understood. Overexpression of KLF6-SV1 inhibits the KLF6 gene function while promoting tumor progression, which is associated with a poor prognosis in patients with various malignancies. We reviewed the progress of KLF6-SV1 research in NSCLC over the last several years to understand the molecular mechanisms of tumorigenesis, tumor development, and therapy resistance. Finally, this review emphasizes the therapeutic potential of small interfering RNA targeted silencing of KLF6-SV1 as a novel strategy for managing chemotherapy resistance in NSCLC patients.

Indexed as

chemotherapy resistanceEMTKLF6-SV1NSCLCproliferationsiRNA

Identifiers

PMID36381325
PMCPMC9641401
OpenAlexW4309245024

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.